L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Phase 2 Completed 70 enrolled Emmaus Medical, Inc. FDA Office of Orphan Products Development · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.

Timeline

Start: 2004-03
Primary completion: 2008-07
Completion: 2008-07

Publications

Bolarinwa AB, Oduwole O, Okebe J, Ogbenna AA, Otokiti OE, Olatinwo AT. Antioxidant supplementation for sickle cell disease. Cochrane Database Syst Rev. 2024 May 22;5(5):CD013590. doi: 10.1002/14651858.CD013590.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glutamine	Other / unclassified	0.3 g/kg	Oral

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Summary

Timeline

Publications

Drugs

Indications